Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
European Journal of Pharmacology
|
May 10, 2017
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist
Karin J Stebbins, Alex R Broadhead, Geraldine Cabrera, et al.
European Journal of Pharmacology
|
May 8, 2010
Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation
Karin J Stebbins, Alex R Broadhead, Lucia D Correa, et al.
International Archives of Allergy and Immunology
|
November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus
Karin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
January 31, 2019
Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors
Kelsey A Rankin, Feng Mei, Kicheol Kim, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2010
5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 1, 2011
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
Jill M Scott, Christopher Baccei, Gretchen Bain, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 31, 2018
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies
Jason D Jacintho, Christopher S Baccei, Yalda Bravo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 26, 2003
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
European Journal of Pharmacology
|
May 10, 2017
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist
Karin J Stebbins, Alex R Broadhead, Geraldine Cabrera, et al.
European Journal of Pharmacology
|
May 8, 2010
Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation
Karin J Stebbins, Alex R Broadhead, Lucia D Correa, et al.
International Archives of Allergy and Immunology
|
November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus
Karin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
January 31, 2019
Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors
Kelsey A Rankin, Feng Mei, Kicheol Kim, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2010
5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 1, 2011
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
Jill M Scott, Christopher Baccei, Gretchen Bain, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 31, 2018
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies
Jason D Jacintho, Christopher S Baccei, Yalda Bravo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 26, 2003
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
Page
of 7